JP2019524789A - ピペラジン誘導体、医薬組成物、及びその使用方法 - Google Patents
ピペラジン誘導体、医薬組成物、及びその使用方法 Download PDFInfo
- Publication number
- JP2019524789A JP2019524789A JP2019506346A JP2019506346A JP2019524789A JP 2019524789 A JP2019524789 A JP 2019524789A JP 2019506346 A JP2019506346 A JP 2019506346A JP 2019506346 A JP2019506346 A JP 2019506346A JP 2019524789 A JP2019524789 A JP 2019524789A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- use according
- following formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title abstract description 30
- 150000004885 piperazines Chemical class 0.000 title abstract description 17
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 315
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 99
- 201000011510 cancer Diseases 0.000 claims abstract description 68
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 33
- 201000010099 disease Diseases 0.000 claims abstract description 30
- 230000003463 hyperproliferative effect Effects 0.000 claims abstract description 22
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 208000006994 Precancerous Conditions Diseases 0.000 claims abstract description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 44
- 229910052760 oxygen Inorganic materials 0.000 claims description 39
- 229910052736 halogen Inorganic materials 0.000 claims description 38
- 150000002367 halogens Chemical class 0.000 claims description 37
- 125000001072 heteroaryl group Chemical group 0.000 claims description 35
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 23
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 22
- 201000005202 lung cancer Diseases 0.000 claims description 22
- 208000020816 lung neoplasm Diseases 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 206010027476 Metastases Diseases 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000005493 quinolyl group Chemical group 0.000 claims description 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 14
- 206010025323 Lymphomas Diseases 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 206010009944 Colon cancer Diseases 0.000 claims description 10
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 10
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 10
- 201000005962 mycosis fungoides Diseases 0.000 claims description 10
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 10
- 206010060862 Prostate cancer Diseases 0.000 claims description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
- 206010039491 Sarcoma Diseases 0.000 claims description 9
- 208000029742 colonic neoplasm Diseases 0.000 claims description 9
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 7
- 201000010881 cervical cancer Diseases 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 6
- 208000009956 adenocarcinoma Diseases 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 208000017604 Hodgkin disease Diseases 0.000 claims description 5
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 5
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 5
- 239000000829 suppository Substances 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 238000001361 intraarterial administration Methods 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 201000003076 Angiosarcoma Diseases 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 3
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 3
- 206010027465 Metastases to skin Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 206010024627 liposarcoma Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000003708 skin melanoma Diseases 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 201000009047 Chordoma Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 210000004100 adrenal gland Anatomy 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 208000006359 hepatoblastoma Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 claims description 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000001611 myxosarcoma Diseases 0.000 claims description 2
- 208000025189 neoplasm of testis Diseases 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 208000029255 peripheral nervous system cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 208000000516 mast-cell leukemia Diseases 0.000 claims 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 43
- 238000002360 preparation method Methods 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 59
- -1 methoxyphenyl Chemical group 0.000 description 33
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 10
- 239000012453 solvate Substances 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 229940127089 cytotoxic agent Drugs 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 0 *[U](CC1)CCN1C(*1c2ccccc2-c2c1cccc2)=O Chemical compound *[U](CC1)CCN1C(*1c2ccccc2-c2c1cccc2)=O 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012055 enteric layer Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 208000003747 lymphoid leukemia Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 2
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000009621 actinic keratosis Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000004212 difluorophenyl group Chemical group 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910001411 inorganic cation Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 150000002892 organic cations Chemical class 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-LDWIPMOCSA-N (?)-Camphoric acid Chemical compound CC1(C)[C@@H](C(O)=O)CC[C@@]1(C)C(O)=O LSPHULWDVZXLIL-LDWIPMOCSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010048782 Breast calcifications Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- WUUVTZUSGKYHIL-UHFFFAOYSA-N COC(C([N+]1=C(C(NC2=CC=CC=C2)=O)N=NN1)=C1)=CC([N+]([O-])=O)=C1S([O-])(=O)=O Chemical compound COC(C([N+]1=C(C(NC2=CC=CC=C2)=O)N=NN1)=C1)=CC([N+]([O-])=O)=C1S([O-])(=O)=O WUUVTZUSGKYHIL-UHFFFAOYSA-N 0.000 description 1
- NOCZQNXEVRXGAP-UHFFFAOYSA-N COc1cc(N(CC2)CCN2C([n]2c3ccccc3c3c2cccc3)=O)ccc1 Chemical compound COc1cc(N(CC2)CCN2C([n]2c3ccccc3c3c2cccc3)=O)ccc1 NOCZQNXEVRXGAP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 206010008282 Cervical leukoplakia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000035865 Chronic mast cell leukemia Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
- 229930182847 D-glutamic acid Natural products 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023774 Large cell lung cancer Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- WXMRHRKGHIMHNK-UHFFFAOYSA-N O=C([n]1c2ccccc2c2c1cccc2)N(CC1)CCN1c1cc(F)cc(F)c1 Chemical compound O=C([n]1c2ccccc2c2c1cccc2)N(CC1)CCN1c1cc(F)cc(F)c1 WXMRHRKGHIMHNK-UHFFFAOYSA-N 0.000 description 1
- BGKOAAJPNIJAON-UHFFFAOYSA-N O=C([n]1c2ccccc2c2c1cccc2)N(CC1)CCN1c1ccccc1 Chemical compound O=C([n]1c2ccccc2c2c1cccc2)N(CC1)CCN1c1ccccc1 BGKOAAJPNIJAON-UHFFFAOYSA-N 0.000 description 1
- 206010031023 Oral submucosal fibrosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-O benzylaminium Chemical compound [NH3+]CC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-O 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-O bis(2-hydroxyethyl)azanium Chemical compound OCC[NH2+]CCO ZBCBWPMODOFKDW-UHFFFAOYSA-O 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000010225 mixed cell type cancer Diseases 0.000 description 1
- 208000029638 mixed neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 208000005207 oral submucous fibrosis Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000001350 reed-sternberg cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000001216 uterine cervix leukoplakia Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/38—[b, e]-condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
- C07D335/12—Thioxanthenes
- C07D335/14—Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Description
U及びZは、それぞれ独立して、NまたはCHであり、
Xは、O、NH、S、または結合手であり、
Yは、CH2、C=O、またはC=Sであり、
R1は、アリール、ヘテロアリール、またはC(=O)−ORaであり、任意選択で、アリール及びヘテロアリールはそれぞれ、1以上のアルキル、アリールアルキル、ハロゲン、NO2、CN、OR4、NR5aR5b、またはそれらの任意の組み合わせで置換され、
R2及びR3は、それぞれ独立して、ハロゲン、NO2、CN、C1−C4アルキル、OR4、及びNR5aR5bからなる群より選択され、
R4、Ra、R5a、及びR5bは、それぞれ独立して、水素またはC1−C4アルキルであり、
nは、0または1であり、
mは、0、1、または2であり、
p及びqは、それぞれ独立して、0、1、2、3、及び4から選択される。
ただし、
(1)ZがCHである場合、Xは、NH、S、または結合手である。
(2)次の化合物は除外される。
(i)XがNHであり、ZがCHであり、YがC=Oであり、nが0であり、mが0であり、R1が1以上のアルコキシで置換されたフェニルであり、かつp及びqがそれぞれ0である式(II)の化合物、及び
(ii)XがSであり、ZがNであり、YがC=Oであり、nが0であり、mが0であり、R1がピリジニルであり、かつp及びqがそれぞれ0である式(II)の化合物。
U及びZは、それぞれ独立して、NまたはCHであり、
Xは、O、NH、S、または結合手であり、
Yは、CH2、C=O、またはC=Sであり、
R1は、アリール、ヘテロアリール、またはC(=O)−ORaであり、任意選択で、アリール及びヘテロアリールはそれぞれ、1以上のアルキル、アリールアルキル、ハロゲン、NO2、CN、OR4、NR5aR5b、またはそれらの任意の組み合わせで置換され、
R2及びR3は、それぞれ独立して、ハロゲン、NO2、CN、C1−C4アルキル、OR4、及びNR5aR5bからなる群より選択され、
R4、Ra、R5a、及びR5bは、それぞれ独立して、水素またはC1−C4アルキルであり、
nは、0または1であり、
mは、0、1、または2であり、
p及びqは、それぞれ独立して、0、1、2、3、及び4から選択される。
ただし、
(1)ZがCHである場合、Xは、NH、S、または結合手である。
(2)次の化合物は除外される。
(i)XがNHであり、ZがCHであり、YがC=Oであり、nが0であり、mが0であり、R1が1以上のアルコキシで置換されたフェニルであり、かつp及びqがそれぞれ0である式(II)の化合物、及び
(ii)XがSであり、ZがNであり、YがC=Oであり、nが0であり、mが0であり、R1がピリジニルであり、かつp及びqがそれぞれ0である式(II)の化合物。
U及びZは、それぞれ独立して、NまたはCHであり、
Xは、O、NH、S、または結合手であり、
Yは、CH2、C=O、またはC=Sであり、
R1は、アリール、ヘテロアリール、またはC(=O)−ORaであり、任意選択で、アリール及びヘテロアリールはそれぞれ、1以上のアルキル、アリールアルキル、ハロゲン、NO2、CN、OR4、NR5aR5b、またはそれらの任意の組み合わせで置換され、
R2及びR3は、それぞれ独立して、ハロゲン、NO2、CN、C1−C4アルキル、OR4、及びNR5aR5bからなる群より選択され、
R4、Ra、R5a、及びR5bは、それぞれ独立して、水素またはC1−C4アルキルであり、
nは、0または1であり、
mは、0、1、または2であり、
p及びqは、それぞれ独立して、0、1、2、3、及び4から選択される。
ただし、ZがCHである場合、Xは、NH、S、または結合手である。
(a)フェニル
(b)フルオロフェニル
(c)ジフルオロフェニル
(d)ペンタフルオロフェニル
(e)メトキシフェニル
(f)下記の化合物
(1)ZがCHである場合、Xは、NH、S、または結合手である。
(2)XがSである場合、ZはCHである。
(3)次の化合物は除外される。XがNHであり、ZがCHであり、YがC=Oであり、nが0であり、mが0であり、R1が1以上のアルコキシで置換されたフェニルであり、かつp及びqがそれぞれ0である式(II)の化合物。
(1)ZがCHである場合、Xは、NH、S、または結合手である。
(2)次の化合物は除外される。
(i)XがNHであり、ZがCHであり、YがC=Oであり、nが0であり、mが0であり、R1が1以上のアルコキシで置換されたフェニルであり、かつp及びqがそれぞれ0である式(II)の化合物、及び
(ii)XがSであり、ZがNであり、YがC=Oであり、nが0であり、mが0であり、R1が非置換または置換されたフェニルであり、かつp及びqがそれぞれ0である式(II)の化合物。
(1)ZがCHである場合、Xは、NH、S、または結合手である。
(2)次の化合物は除外される。
(i)XがNHであり、ZがCHであり、YがC=Oであり、nが0であり、mが0であり、R1が1以上のアルコキシで置換されたフェニルであり、かつp及びqがそれぞれ0である式(II)の化合物、及び
(ii)XがSであり、ZがNであり、YがC=Oであり、nが0であり、mが0であり、R1がピリジニルであり、かつp及びqがそれぞれ0である式(II)の化合物。
U及びZは、それぞれ独立して、NまたはCHであり、
Xは、O、NH、S、または結合手であり、
Yは、CH2、C=O、またはC=Sであり、
R1は、アリール、ヘテロアリール、またはC(=O)−ORaであり、任意選択で、アリール及びヘテロアリールはそれぞれ、1以上のアルキル、アリールアルキル、ハロゲン、NO2、CN、OR4、NR5aR5b、またはそれらの任意の組み合わせで置換され、
R2及びR3は、それぞれ独立して、ハロゲン、NO2、CN、C1−C4アルキル、OR4、及びNR5aR5bからなる群より選択され、
R4、Ra、R5a、及びR5bは、それぞれ独立して、水素またはC1−C4アルキルであり、
nは、0または1であり、
mは、0、1、または2であり、
p及びqは、それぞれ独立して、0、1、2、3、及び4から選択される。
(i)XがNHであり、ZがCHであり、YがC=Oであり、nが0であり、mが0であり、R1が1以上のアルコキシで置換されたフェニルであり、かつp及びqがそれぞれ0である式(II)の化合物、及び
(ii)XがSであり、ZがNであり、YがC=Oであり、nが0であり、mが0であり、R1が非置換または置換されたフェニルであり、かつp及びqがそれぞれ0である式(II)の化合物。
いくつかの癌細胞株におけるピペラジン誘導体の細胞毒性
(A)HCT116−ヒト大腸癌細胞株(Colon)
(B)Hela−ヒト子宮頸部腺癌細胞株(Cervix)
(C)H358−ヒト肺癌細胞株(Lung)
(D)Panc−1−ヒト膵臓癌細胞株(Pancreatic)
肺癌細胞における別のピペラジン誘導体の細胞毒性
条件:H358肺癌株、11.5mMグルコース、5000細胞/ウェル、0.5%FCS、72時間。
条件:H358肺癌株、11.5mMグルコース、5000細胞/ウェル、0.5%FCS、72時間。
条件:PC3前立腺癌細胞株、25mMグルコース、1500細胞/ウェル、10%FCS、72時間。
Claims (58)
- 下記の式(II)で表される化合物、またはその薬学的に許容される塩。
U及びZは、それぞれ独立して、NまたはCHであり、
Xは、O、NH、S、または結合手であり、
Yは、CH2、C=O、またはC=Sであり、
R1は、アリール、ヘテロアリール、またはC(=O)−ORaであり、任意選択で、アリール及びヘテロアリールはそれぞれ、1以上のアルキル、アリールアルキル、ハロゲン、NO2、CN、OR4、NR5aR5b、またはそれらの任意の組み合わせで置換され、
R2及びR3は、それぞれ独立して、ハロゲン、NO2、CN、C1−C4アルキル、OR4、及びNR5aR5bからなる群より選択され、
R4、Ra、R5a、及びR5bは、それぞれ独立して、水素またはC1−C4アルキルであり、
nは、0または1であり、
mは、0、1、または2であり、
p及びqは、それぞれ独立して、0、1、2、3、及び4から選択される。
ただし、
(1)ZがCHである場合、Xは、NH、S、または結合手である。
(2)次の化合物は除外される。
(i)XがNHであり、ZがCHであり、YがC=Oであり、nが0であり、mが0であり、R1が1以上のアルコキシで置換されたフェニルであり、かつp及びqがそれぞれ0である式(II)の化合物、及び
(ii)XがSであり、ZがNであり、YがC=Oであり、nが0であり、mが0であり、R1がピリジニルであり、かつp及びqがそれぞれ0である式(II)の化合物。 - 前記m及びnがそれぞれ0である、請求項1に記載の化合物。
- 前記R1が、アリールまたはヘテロアリールである、請求項1または2に記載の化合物。
- 前記R1が、フェニル、キノリル、またはイソキノリルである、請求項1または2に記載の化合物。
- 前記R1が、フェニルであり、任意選択で、1以上のハロゲン、CN、C1−C4アルキル、OR4、またはそれらの任意の組み合わせで置換される、請求項1または2に記載の化合物。
- 前記R1が、C(=O)−ORaであり、RaがC1−C4アルキルである、請求項1または2に記載の化合物。
- 前記pが0である、請求項1ないし6のいずれか一項に記載の化合物。
- 前記qが0である、請求項1ないし7のいずれか一項に記載の化合物。
- 前記UがNである、請求項1ないし8のいずれか一項に記載の化合物。
- 前記Xが、O、NH、または結合手である、請求項1ないし9のいずれか一項に記載の化合物。
- 前記ZがNである、請求項11に記載の化合物。
- 前記XがOである、請求項18に記載の化合物。
- 請求項1ないし22のいずれか一項に記載の化合物、またはその薬学的に許容される塩と、
薬学的に許容される担体と、を含有する医薬組成物。 - 対象における癌、前癌状態、または良性過剰増殖性疾患の治療における使用のための、下記の式(II)で表される化合物、またはその薬学的に許容される塩。
U及びZは、それぞれ独立して、NまたはCHであり、
Xは、O、NH、S、または結合手であり、
Yは、CH2、C=O、またはC=Sであり、
R1は、アリール、ヘテロアリール、またはC(=O)−ORaであり、任意選択で、アリール及びヘテロアリールはそれぞれ、1以上のアルキル、アリールアルキル、ハロゲン、NO2、CN、OR4、NR5aR5b、またはそれらの任意の組み合わせで置換され、
R2及びR3は、それぞれ独立して、ハロゲン、NO2、CN、C1−C4アルキル、OR4、及びNR5aR5bからなる群より選択され、
R4、Ra、R5a、及びR5bは、それぞれ独立して、水素またはC1−C4アルキルであり、
nは、0または1であり、
mは、0、1、または2であり、
p及びqは、それぞれ独立して、0、1、2、3、及び4から選択される。
ただし、
(1)ZがCHである場合、Xは、NH、S、または結合手である。
(2)次の化合物は除外される。
(i)XがNHであり、ZがCHであり、YがC=Oであり、nが0であり、mが0であり、R1が1以上のアルコキシで置換されたフェニルであり、かつp及びqがそれぞれ0である式(II)の化合物、及び
(ii)XがSであり、ZがNであり、YがC=Oであり、nが0であり、mが0であり、R1がピリジニルであり、かつp及びqがそれぞれ0である式(II)の化合物。 - 前記m及びnがそれぞれ0である、請求項24に記載の前記使用のための化合物。
- 前記R1が、アリールまたはヘテロアリールである、請求項24または25に記載の前記使用のための化合物。
- 前記R1が、フェニル、キノリル、またはイソキノリルである、請求項24または25に記載の前記使用のための化合物。
- 前記R1が、フェニルであり、任意選択で、1以上のハロゲン、CN、C1−C4アルキル、OR4、またはそれらの任意の組み合わせで置換される、請求項24または25に記載の前記使用のための化合物。
- 前記R1が、C(=O)−ORaであり、RaがC1−C4アルキルである、請求項24または25に記載の前記使用のための化合物。
- 前記pが0である、請求項24ないし29のいずれか一項に記載の前記使用のための化合物。
- 前記qが0である、請求項24ないし30のいずれか一項に記載の前記使用のための化合物。
- 前記UがNである、請求項24ないし31のいずれか一項に記載の前記使用のための化合物。
- 前記Xが、O、NH、または結合手である、請求項24ないし32のいずれか一項に記載の前記使用のための化合物。
- 前記ZがNである、請求項34に記載の前記使用のための化合物。
- 前記XがOである、請求項41に記載の前記使用のための化合物。
- 前記対象が哺乳動物である、請求項24ないし45のいずれか一項に記載の前記使用のための化合物。
- 前記哺乳動物がヒトである、請求項46に記載の前記使用のための化合物。
- 前記癌が固形腫瘍を含む、請求項24ないし47のいずれか一項に記載の前記使用のための化合物。
- 前記固形腫瘍が、前立腺癌またはその転移したものを含む、請求項48に記載の前記使用のための化合物。
- 前記固形腫瘍が、膵臓癌またはその転移したものを含む、請求項48に記載の前記使用のための化合物。
- 前記固形腫瘍が、結腸癌、子宮頸癌、肺癌、乳癌、肝臓癌、皮膚癌、黒色腫、またはそれらの転移したものを含む、請求項48に記載の前記使用のための化合物。
- 前記癌が、扁平上皮癌(SCC)、基底細胞癌(BCC)、皮膚T細胞リンパ腫(CTCL)、またはそれらの転移したものを含む、請求項24ないし47のいずれか一項に記載の前記使用のための化合物。
- 前記癌が、結腸癌、子宮頸癌、肺癌、膵臓癌、乳癌、肝臓癌、皮膚癌、黒色腫、リンパ増殖性疾患、卵巣癌、前立腺癌、子宮内膜癌、骨癌、胃癌、甲状腺癌、頭頸部癌、中枢神経系癌、末梢神経系癌、腎臓癌、肝細胞癌、肝癌、肝芽腫、横紋筋肉腫、食道癌、甲状腺癌、神経節芽腫、線維肉腫、粘液肉腫、脂肪肉腫、軟骨肉腫、骨原性肉腫、脊索腫、血管肉腫、内皮肉腫、ユーイング腫瘍、平滑筋肉腫、横紋皮肉腫、浸潤性腺管癌、乳頭腺癌、腺癌、腎細胞癌、副腎腫、副腎様腺癌、胆管癌、絨毛癌、セミノーマ、胚性癌、ウィルムス腫瘍、精巣腫瘍、肺癌、膀胱癌、神経膠腫、星細胞腫、髄芽腫、頭蓋咽頭腫、上衣腫、松果体腫、網膜芽細胞腫、神経芽細胞腫、結腸癌、直腸癌、造血器腫瘍、血液系腫瘍、またはそれらの転移したものを含む、請求項24ないし47のいずれか一項に記載の前記使用のための化合物。
- 前記癌が、血液癌を含み、
該血液癌が、急性骨髄性白血病、急性骨髄球性白血病、急性リンパ性白血病、急性リンパ性白血病、慢性骨髄性白血病、慢性リンパ性白血病、肥満細胞性白血病、多発性骨髄腫、骨髄性リンパ腫、ホジキンリンパ腫、非ホジキンリンパ腫、皮膚T細胞性リンパ腫、またはそれらの転移したものを含む、請求項24ないし47のいずれか一項に記載の前記使用のための化合物。 - 当該化合物が、癌、前癌状態、または過剰増殖性疾患の治療に有効な少なくとも1つの別の薬剤と組み合わされる、請求項24ないし54のいずれか一項に記載の前記使用のための化合物。
- 当該化合物が、非経口投与、経口投与、直腸投与、鼻腔内投与、局所投与、吸入による投与、または座薬による投与用に製剤化されている、請求項24ないし55のいずれか一項に記載の前記使用のための化合物。
- 前記非経口投与が、静脈内投与、皮下投与、腹腔内投与、動脈内投与、経皮投与、または筋肉内投与である、請求項56に記載の前記使用のための化合物。
- 当該化合物が、静脈内投与用に製剤化されている、請求項24ないし55のいずれか一項に記載の前記使用のための化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662376396P | 2016-08-18 | 2016-08-18 | |
US62/376,396 | 2016-08-18 | ||
PCT/IL2017/050909 WO2018033918A1 (en) | 2016-08-18 | 2017-08-17 | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019524789A true JP2019524789A (ja) | 2019-09-05 |
JPWO2018033918A5 JPWO2018033918A5 (ja) | 2024-02-14 |
JP7471818B2 JP7471818B2 (ja) | 2024-04-22 |
Family
ID=61196523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019506346A Active JP7471818B2 (ja) | 2016-08-18 | 2017-08-17 | ピペラジン誘導体、医薬組成物、及びその使用方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US11084807B2 (ja) |
JP (1) | JP7471818B2 (ja) |
CN (1) | CN109641884B (ja) |
AU (1) | AU2017311691B2 (ja) |
CA (1) | CA3034211A1 (ja) |
WO (1) | WO2018033918A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018033918A1 (en) * | 2016-08-18 | 2018-02-22 | Vidac Pharma Ltd. | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
EP3565555A4 (en) | 2016-11-07 | 2021-03-17 | VIDAC Pharma Ltd. | USE OF HEXKINASE-2 / MITOCHONDRIAL DISCONNECTORS FOR TREATMENT OF HEXKINASE-2 (HC2) EXPRESSING CANCER DISEASES |
US10682346B2 (en) * | 2016-11-07 | 2020-06-16 | Vidac Pharma Ltd. | Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses |
EP3554494A4 (en) | 2016-12-19 | 2021-02-17 | Cellixbio Private Limited | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION |
CN110003204B (zh) * | 2019-04-30 | 2020-08-11 | 上海勋和医药科技有限公司 | 一种bet蛋白抑制剂、其制备方法及用途 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5029572A (ja) * | 1973-02-20 | 1975-03-25 | ||
JPH03251564A (ja) * | 1990-02-26 | 1991-11-11 | Taisho Pharmaceut Co Ltd | ジメチルカルバゾール誘導体 |
WO1994018197A1 (en) * | 1993-02-04 | 1994-08-18 | Meiji Seika Kabushiki Kaisha | Compound with antipsychotic effect |
JPH11503127A (ja) * | 1995-04-07 | 1999-03-23 | ノボ ノルディスク アクティーゼルスカブ | 新規なヘテロ環式化合物 |
WO1999031085A1 (fr) * | 1997-12-12 | 1999-06-24 | Japan Tobacco Inc. | Derives du 3-piperidyl-4-oxoquinazoline et compositions medicinales les contenant |
JP2004504381A (ja) * | 2000-07-21 | 2004-02-12 | ツェンタリス アクチエンゲゼルシャフト | 新規のヘテロアリール誘導体および医薬としてのその使用 |
JP2005538968A (ja) * | 2002-06-29 | 2005-12-22 | ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | アリール−及びヘテロアリールカルボニルピペラジン及び良性及び悪性の腫瘍疾患を治療するためのその使用 |
WO2007076055A2 (en) * | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR7036E (ja) | ||||
BE486462A (ja) | ||||
US2742472A (en) | 1956-04-17 | Spasmolytic pipergzjnes | ||
NL71566C (ja) | 1948-10-30 | |||
GB666457A (en) | 1948-10-30 | 1952-02-13 | Henri Morren | Carbonyl chlorides and monocarboxyamides of piperazine and process for the preparation thereof |
GB748812A (en) | 1952-12-15 | 1956-05-09 | Abbott Lab | Improvements in or relating to piperazine derivatives and process of preparing the same |
CH333366A (de) | 1953-09-04 | 1958-10-15 | Ciba Geigy | Verfahren zur Herstellung neuer Pyridazone |
DE954155C (de) | 1954-01-08 | 1956-12-13 | Schering Ag | Verfahren zur Herstellung von 4-Aminochromanen |
GB773756A (en) | 1954-08-18 | 1957-05-01 | Searle & Co | 9-aminoalkyl-9-xanthenecarboxamides and derivatives thereof |
GB781528A (en) | 1954-09-10 | 1957-08-21 | American Cyanamid Co | Substituted ethylene dipiperazines |
GB778309A (en) | 1954-11-12 | 1957-07-03 | Rhone Poulenc Sa | 4-o.o-diphenyl-phosphorylamido-pyrazolones |
NL202935A (ja) | 1954-12-23 | |||
GB777209A (en) | 1954-12-28 | 1957-06-19 | Wellcome Found | Improvements in or relating to piperazine derivatives |
US2838509A (en) | 1956-10-02 | 1958-06-10 | Searle & Co | 9-aminoalkyl-9-xanthenecarboxamides |
FR1192168A (fr) | 1957-04-11 | 1959-10-23 | Préparation de la nu-thiodiphénylcarbamyl piperazine | |
US2887481A (en) | 1957-04-29 | 1959-05-19 | Schering Corp | Heterocyclic amides |
US3284449A (en) | 1964-12-29 | 1966-11-08 | Searle & Co | Hydrazones of 1-amino-4-xanthenecar-bonylpiperazines |
NL129629C (ja) | 1965-07-02 | |||
FR6541M (ja) | 1967-05-10 | 1968-12-16 | ||
US3700658A (en) | 1967-07-05 | 1972-10-24 | Adolf Steinhofer | N-alkyl-n-arylcarbamoyl lactams |
DE1720281A1 (de) | 1967-07-05 | 1971-06-09 | Basf Ag | Verfahren zum Beschleunigen der anionischen Polymerisation von Lactamen |
US3585171A (en) | 1967-07-05 | 1971-06-15 | Basf Ag | Accelerating the anionic polymerization of lactams |
DE1770968A1 (de) | 1968-07-24 | 1972-01-13 | Bayer Ag | Verfahren zur Herstellung von Polyamiden |
GB1282336A (en) | 1970-03-25 | 1972-07-19 | Rech S Et D Applic Scient Soge | Thiaxanthene derivatives and their preparation |
US3803141A (en) | 1972-08-14 | 1974-04-09 | Burdick & Jackson Labor Inc | 10-(1-substituted-3-pyrrolidylmethyl)phenothiazines |
US3838118A (en) * | 1973-02-20 | 1974-09-24 | Janssen Pharmaceutica Nv | ((thioxanthenyl)propyl)-piperidyl-benzimidazolinones |
DE2519583A1 (de) | 1975-05-02 | 1976-11-18 | Basf Ag | Thermoplastische polybutylenterephthalat-formmassen |
JPS5334779A (en) | 1976-09-09 | 1978-03-31 | Kissei Pharmaceut Co Ltd | Novel piperazine derivatives and thier preparation |
US4188485A (en) | 1978-06-16 | 1980-02-12 | G. D. Searle & Co. | 1-[(10,11-Dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)methyl]-4-substituted piperidines and related compounds |
CH653675A5 (en) | 1983-05-26 | 1986-01-15 | Ciba Geigy Ag | Microbicides |
DE3607194A1 (de) | 1986-03-05 | 1987-09-10 | Merck Patent Gmbh | Carbamoylphenothiazine |
US4812462A (en) | 1986-04-01 | 1989-03-14 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity |
US5223508A (en) | 1988-12-27 | 1993-06-29 | Kirin Beer Kabushiki Kaisha | Pyridyl carboximidamide compounds useful in treating blood pressure |
JPH04130429A (ja) | 1990-09-21 | 1992-05-01 | Konica Corp | ハロゲン化銀写真感光材料 |
JP2696434B2 (ja) | 1991-01-23 | 1998-01-14 | 富士写真フイルム株式会社 | 画像形成方法 |
JPH04356466A (ja) | 1991-01-28 | 1992-12-10 | Mitsui Toatsu Chem Inc | 新規キノリン誘導体及びそれを有効成分として含有する制癌剤効果増強剤 |
JPH05273701A (ja) | 1992-03-26 | 1993-10-22 | Konica Corp | ハロゲン化銀カラー写真感光材料 |
DE4215213A1 (de) | 1992-05-09 | 1993-11-11 | Merck Patent Gmbh | Arylacetamide |
JPH06211664A (ja) | 1993-01-20 | 1994-08-02 | Pola Chem Ind Inc | 薬剤に対する感受性回復剤 |
JPH06228095A (ja) | 1993-02-04 | 1994-08-16 | Kirin Brewery Co Ltd | カルバゾール誘導体 |
DE69425882T2 (de) | 1993-03-29 | 2001-01-11 | Basf Ag | 1-amino-3-phenoxy-propan-derivate als modulatoren bei multi-drug resistenz |
US6071901A (en) * | 1994-01-04 | 2000-06-06 | Novo Nordisk A/S | Substituted dibenz[b,f]azepines and uses thereof |
DE4430091A1 (de) | 1994-08-25 | 1996-02-29 | Bayer Ag | Verwendung von N-substituierten Phenothiazinen |
JPH08110621A (ja) | 1994-10-12 | 1996-04-30 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー感光材料 |
JPH08217758A (ja) | 1995-02-09 | 1996-08-27 | Nissan Chem Ind Ltd | 4−ハロアルキルピリミジン−5−カルボン酸アニライド誘導体 |
US5795894A (en) | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
AU3172397A (en) | 1996-06-05 | 1998-01-05 | Novartis Ag | Anti-neurodegeneratively effective xanthene derivatives |
JPH11292840A (ja) | 1998-04-06 | 1999-10-26 | Soyaku Gijutsu Kenkyusho:Kk | ノルスタチン誘導体又はその塩 |
TW593241B (en) | 1999-04-20 | 2004-06-21 | Hoffmann La Roche | Carbamic acid derivatives |
WO2001040227A1 (fr) | 1999-12-03 | 2001-06-07 | Ono Pharmaceutical Co., Ltd. | Derives triazaspiro[5.5]undecane et medicaments contenant ces derives en tant que principe actif |
US6436972B1 (en) | 2000-04-10 | 2002-08-20 | Dalhousie University | Pyridones and their use as modulators of serine hydrolase enzymes |
GB0012362D0 (en) | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
CA2310205A1 (en) | 2000-05-29 | 2001-11-29 | Dalhousie University | Unknown |
JP2002047272A (ja) | 2000-07-26 | 2002-02-12 | Dai Ichi Seiyaku Co Ltd | ポリアミンアミド誘導体 |
US6800619B2 (en) | 2000-09-13 | 2004-10-05 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
US6727364B2 (en) | 2001-04-30 | 2004-04-27 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
EP1499898A2 (en) | 2002-04-19 | 2005-01-26 | Vertex Pharmaceuticals Incorporated | Regulation of tnf-alpha |
US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
BRPI0314001B8 (pt) | 2002-09-04 | 2021-05-25 | Merck Sharp & Dohme | pirazolopirimidinas como inibidores de cinase dependente de ciclina e composição farmacêutica compreendendo as mesmas |
US8673924B2 (en) | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
EP1571146A4 (en) | 2002-12-10 | 2010-09-01 | Ono Pharmaceutical Co | NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE |
US20040147502A1 (en) | 2002-12-17 | 2004-07-29 | Bisacchi Gregory S. | Beta lactam compounds and their use as inhibitors of tryptase |
DE10348023A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
AU2005249503B2 (en) | 2003-11-10 | 2011-08-25 | Vertex Pharmaceuticals Incorporated | ICE inhibitors for the treatment of autoinflammatory diseases |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
MY149978A (en) | 2003-12-15 | 2013-11-15 | Merck Sharp & Dohme | Heterocyclic aspartyl protease inhibitors |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
WO2005111025A1 (en) | 2004-04-29 | 2005-11-24 | Aventis Pharmaceuticals Inc. | 3-piperidinylisochroman-5-ols as dopamine agonists |
US7635698B2 (en) | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
GB0500300D0 (en) | 2005-01-07 | 2005-02-16 | Ionix Pharmaceuticals Ltd | Chemical compositions |
WO2006105056A2 (en) | 2005-03-28 | 2006-10-05 | Fmc Corporation | Insecticidal 2,4-diaminoquinazolines and related derivatives |
DE102005044813A1 (de) | 2005-05-19 | 2007-10-04 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
WO2007013691A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | スピロ環化合物 |
EP2402321A3 (en) | 2005-12-07 | 2012-02-29 | Ramot at Tel Aviv University, Ltd. | Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof |
WO2007098086A2 (en) | 2006-02-17 | 2007-08-30 | Avalon Pharmaceuticals | Hydroxypiperidine derivatives and uses thereof |
US20080051387A1 (en) | 2006-06-09 | 2008-02-28 | Yuelian Xu | Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
GB0614365D0 (en) | 2006-07-19 | 2006-08-30 | Proaxon Ltd | Pharmaceutical compositions and their use |
AU2007275415A1 (en) | 2006-07-20 | 2008-01-24 | Ligand Pharmaceuticals Incorporated | Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation |
US20100179118A1 (en) | 2006-09-08 | 2010-07-15 | Dainippon Sumitomo Pharma Co., Ltd. | Cyclic aminoalkylcarboxamide derivative |
RU2329044C1 (ru) | 2006-11-16 | 2008-07-20 | Андрей Александрович Иващенко | Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство |
US8202891B2 (en) | 2007-04-24 | 2012-06-19 | Theravance, Inc. | Quaternary ammonium compounds useful as muscarinic receptor antagonists |
JP2011504499A (ja) | 2007-11-21 | 2011-02-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | トリプターゼ阻害剤として使用するためのスピロピペリジン |
EP2222637A1 (en) | 2007-12-14 | 2010-09-01 | Theravance, Inc. | Amidine-containing compounds useful as muscarinic receptor antagonists |
CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
WO2009100872A1 (en) | 2008-02-12 | 2009-08-20 | Boehringer Ingelheim International Gmbh | Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use |
WO2010021717A2 (en) | 2008-08-20 | 2010-02-25 | Sequoia Pharmaceuticals, Inc. | Hcv protease inhibitors |
US20100248365A1 (en) | 2009-03-27 | 2010-09-30 | Zacharon Pharmaceuticals, Inc. | Ganglioside biosynthesis modulators |
AR076928A1 (es) | 2009-05-28 | 2011-07-20 | Otsuka Pharma Co Ltd | Derivados de 3h-pirido[4, 3-d]pirimidin-4-ona, un metodo para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el estres. |
CA2798330A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
TW201236239A (en) | 2010-11-16 | 2012-09-01 | Solvay | Rechargeable metal or metal-ion cell |
JP2012111731A (ja) | 2010-11-26 | 2012-06-14 | Otsuka Pharmaceut Co Ltd | 医薬 |
CN104906103B (zh) | 2010-12-14 | 2018-05-18 | 电泳有限公司 | 酪蛋白激酶1δ(CK1δ)抑制剂 |
CN102690717B (zh) | 2011-03-24 | 2014-08-20 | 中国石油化工股份有限公司 | 一种极压长寿命汽轮机润滑油组合物 |
US9108930B2 (en) | 2011-04-06 | 2015-08-18 | The Scripps Research Institute | N1- and N2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
WO2015005901A1 (en) | 2013-07-09 | 2015-01-15 | Bristol-Myers Squibb Company | Combinations of hepatitis c virus inhibitors |
CN103896990B (zh) | 2014-03-12 | 2017-02-08 | 石家庄诚志永华显示材料有限公司 | 有机电致发光材料及其应用 |
CN104109134A (zh) | 2014-06-26 | 2014-10-22 | 陕西科技大学 | 一种n-酰基吩噻嗪及其制备方法 |
CN104109133A (zh) | 2014-06-26 | 2014-10-22 | 陕西科技大学 | 一种制备n-酰基吩噻嗪的方法 |
CN104497013B (zh) | 2014-12-11 | 2017-05-31 | 石家庄诚志永华显示材料有限公司 | 氮杂咔唑类oled材料及其制备方法与应用 |
CN104557875A (zh) | 2015-01-21 | 2015-04-29 | 石家庄诚志永华显示材料有限公司 | 茚并吲哚环状化合物与在有机发光二极管中的应用 |
WO2018033918A1 (en) * | 2016-08-18 | 2018-02-22 | Vidac Pharma Ltd. | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
EP3565555A4 (en) * | 2016-11-07 | 2021-03-17 | VIDAC Pharma Ltd. | USE OF HEXKINASE-2 / MITOCHONDRIAL DISCONNECTORS FOR TREATMENT OF HEXKINASE-2 (HC2) EXPRESSING CANCER DISEASES |
-
2017
- 2017-08-17 WO PCT/IL2017/050909 patent/WO2018033918A1/en active Application Filing
- 2017-08-17 US US15/735,183 patent/US11084807B2/en active Active
- 2017-08-17 AU AU2017311691A patent/AU2017311691B2/en active Active
- 2017-08-17 CN CN201780050775.1A patent/CN109641884B/zh active Active
- 2017-08-17 CA CA3034211A patent/CA3034211A1/en active Pending
- 2017-08-17 JP JP2019506346A patent/JP7471818B2/ja active Active
-
2021
- 2021-08-08 US US17/396,707 patent/US20220098179A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5029572A (ja) * | 1973-02-20 | 1975-03-25 | ||
JPH03251564A (ja) * | 1990-02-26 | 1991-11-11 | Taisho Pharmaceut Co Ltd | ジメチルカルバゾール誘導体 |
WO1994018197A1 (en) * | 1993-02-04 | 1994-08-18 | Meiji Seika Kabushiki Kaisha | Compound with antipsychotic effect |
JPH11503127A (ja) * | 1995-04-07 | 1999-03-23 | ノボ ノルディスク アクティーゼルスカブ | 新規なヘテロ環式化合物 |
WO1999031085A1 (fr) * | 1997-12-12 | 1999-06-24 | Japan Tobacco Inc. | Derives du 3-piperidyl-4-oxoquinazoline et compositions medicinales les contenant |
JP2004504381A (ja) * | 2000-07-21 | 2004-02-12 | ツェンタリス アクチエンゲゼルシャフト | 新規のヘテロアリール誘導体および医薬としてのその使用 |
JP2005538968A (ja) * | 2002-06-29 | 2005-12-22 | ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | アリール−及びヘテロアリールカルボニルピペラジン及び良性及び悪性の腫瘍疾患を治療するためのその使用 |
WO2007076055A2 (en) * | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
Non-Patent Citations (4)
Title |
---|
C. B. POLLARD ET AL.: "Derivatives of Piperazine. XXXIV. Some Reactions of Trimethylene Chlorobromide with 1-Arylpiperazine", JOURNAL OF ORGANIC CHEMISTRY, vol. 24, JPN6021025548, 1959, pages 764 - 767, ISSN: 0004545963 * |
COLLINO,F. ET AL: "Mannich bases of benzimidazoles, benzotriazoles and other analogous compounds, with pharmacological", BOLLETTINO CHIMICO FARMACEUTICO, vol. 121, no. 5, JPN6021025547, 1982, pages 221 - 9, ISSN: 0004851781 * |
GERLACH,M. ET AL: "Design and synthesis of a focused library of novel aryl- and heteroaryl-ketopiperazides", ARCHIV DER PHARMAZIE(WEINHEIM, GERMANY), vol. 337, no. 12, JPN6021025546, 2004, pages 695 - 703, ISSN: 0004851780 * |
STN INTERNATIONAL,FILE REGISTRY [ONLINE],[令和3年6月25日検索],CAS REGISTRY NO. 873579-51-2 (E, JPN7021002427, ISSN: 0004851779 * |
Also Published As
Publication number | Publication date |
---|---|
AU2017311691B2 (en) | 2021-12-02 |
CN109641884B (zh) | 2024-01-02 |
WO2018033918A1 (en) | 2018-02-22 |
AU2017311691A1 (en) | 2019-04-04 |
US20220098179A1 (en) | 2022-03-31 |
US11084807B2 (en) | 2021-08-10 |
US20200031815A1 (en) | 2020-01-30 |
CN109641884A (zh) | 2019-04-16 |
JP7471818B2 (ja) | 2024-04-22 |
CA3034211A1 (en) | 2018-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7471818B2 (ja) | ピペラジン誘導体、医薬組成物、及びその使用方法 | |
JP7449913B2 (ja) | オキサチアジン様化合物を作製する方法 | |
ES2687985T3 (es) | Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer colorrectal | |
JP6433085B2 (ja) | がんの処置に使用するための2−アセチルナフト[2,3−b]フラン−4,9−ジオン | |
CA2736664A1 (en) | The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridinecarboxamide | |
JP6465989B2 (ja) | イソチオシアネート系化合物及びその用途 | |
CA2993363A1 (en) | Naphthofuran compounds and compositions for targeting cancer stem cells | |
BR112018001859B1 (pt) | Comprimido, e, método para produzir um comprimido | |
CN101250183A (zh) | 一种雷贝拉唑的光学异构体及其制备方法、医药用途 | |
CN106661060B (zh) | 菲罗啉膦酸类衍生物及其制备方法和应用 | |
CA3099786A1 (en) | Crystalline form of s-apomorphine | |
CN108864082A (zh) | 一类具有抗癌活性的吲嗪类化合物及其衍生物 | |
CN107325052A (zh) | 一类具有抗癌活性的咪唑酯类化合物及其衍生物 | |
BR112020009596A2 (pt) | combinações de moduladores duplos de irs/stat3 e anticorpos anti pd-1/pd-l1 para tratar câncer | |
JP6469727B2 (ja) | 線維症の抑制又は治療方法 | |
CN113105391B (zh) | 一种具有镇痛活性的高乌甲素衍生物及其制备方法和应用 | |
JP6178010B2 (ja) | 抗腫瘍薬の製造のための置換ベンジルオキシ基含有エーテル化合物の適用 | |
CN108640916A (zh) | 一类具有抗癌活性的硫代吲嗪类化合物及其衍生物 | |
CN104710355A (zh) | 一类含尼克酰胺砌块的二苯基硫脲化合物及其盐的制备方法和用途 | |
JP2019536797A (ja) | 癌の処置のためのチエノイソキノリンおよびその誘導体 | |
CN109705120A (zh) | 一类咪唑并[1,2-a]吡啶化合物及其制备方法和用途 | |
JPH10324644A (ja) | ウレアーゼ阻害物質含有医薬組成物 | |
CN105085479A (zh) | 一种新的含氮杂环化合物 | |
BR112017016776B1 (pt) | Composição e combinação farmacêutica compreendendo um composto d, um inibidor de egfr e/ou um anticorpo egfr |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200817 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210706 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210903 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220106 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220707 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220707 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220715 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220719 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20220826 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20220830 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231222 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20240126 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240410 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7471818 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |